AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
The approval of lamotrigine for bipolar I disorder marks the first time in which a drug that has its most robust effects on the disorder's depressive phase has been approved.
Depressive episodes have been more difficult to treat and prevent than mania in patients with bipolar disorder.
The Food and Drug Administration approved lamotrigine (Lamictal), an antiepileptic marketed by GlaxoSmithKline, specifically for "maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy."
This is also the first approval for maintenance therapy of bipolar disease since lithium was approved in the 1970s and the third drug to be approved for a bipolar indication since 1995, when…